ATS 2024 Final Program

Click on the session title to view the speakers

336

WEDNESDAY • MAY 22

12:00 Nanoluciferase Mycobacteriophage for Rapid Phenotypic TB Diagnosis and Drug-Susceptibility Testing 12:20 Strategies Going Forward to Prevent Emergent Resistance and Optimize MDR-TB Treatment Outcomes

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

D84 EMERGENT RESISTANCE TO NEW DRUGS FOR MDR-TB TREATMENT Assemblies on Pulmonary Infections and Tuberculosis 11:00 a.m. - 12:30 p.m. San Diego Convention Center Room 6D (Upper Level) Target Audience US-based attendees interested in tuberculosis and antimicrobial resistance, International attendees with interest and experience with drug-resistant tuberculosis, public health focused attendees Objectives At the conclusion of this session, the participant will be able to: • define new strategies to treat MDR-TB based on new WHO-endorsed MDR-TB treatment regimens • apply next generation genotypic and phenotypic drug-susceptibility testing and better understand the epidemiology and risk factors for emergent drug-resistance during treatment of MDR-TB • anticipate the direction and limitations of future TB diagnostics in the context of new challenges to global TB control. Multi-drug resistant tuberculosis (MDR-TB) is a challenge for global lung health and represents a growing proportion of all TB cases. Recent studies using entirely novel regimens demonstrate excellent outcomes and lower mortality in MDR-TB treatment. However, resistance to these new antimycobacterial agents is present at baseline and rapidly emerging undermining their promise. Here we present new genomic, basic/translational, and operational insights into antimicrobial resistant tuberculosis and describe new clinical, epidemiologic, and translational strategies to combat this new evolution in drug-resistant tuberculosis. 11:00 Landscape of New Treatments for MDR-TB 11:15 Operational Outcomes from New MDR-TB Treatment Regimens and Emergent Resistance 11:40 Opportunities and Limitations of Genomics for Diagnosing Bedaquiline-Resistant Tuberculosis: an Individual Isolate Meta-Analysis 11:50 Known Unknowns: Resistance Mechanisms to New and Repurposed Drugs to Treat TB

BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

D85 ONE TO RULE THEM ALL? IMMUNE CELLS CONTROL STEM CELL CAPACITY IN THE LUNG Assemblies on Respiratory Cell and Molecular Biology 11:00 a.m. - 12:30 p.m. Marriott Marquis San Diego Marina Grand Ballroom 5-6 (Lobby Level, North Tower) Target Audience Basic researchers and clinicians (clinical scientists) looking for a deeper understanding of the pathomechanisms of COPD. Objectives At the conclusion of this session, the participant will be able to: • understand the effects of innate and adaptive immune cell signaling on alveolar epithelial proliferation and differentiation. • provide insight on how cutting-edge technological advances can delineate immune cell-epithelium crosstalk. • learn how immune targeted pro-regenerative approaches toward reprogramming the alveolar immune niche can open up novel avenues for the treatment of COPD. This session will highlight the important contribution of immune cells to lung regeneration and their crosstalk with lung progenitor cells. It will provide insight on how recent technological advances in omics technologies and human ex vivo lung models can delineate immune cell-epithelium crosstalk and expedite precision pro-regenerative approaches toward reprogramming the alveolar immune niche to treat COPD. 11:00 Immunomechanisms of Lung Regeneration 11:24 Immunometabolic Reprogramming of Epithelial Repair 11:46 Inflammaging Regulates Epithelial Progenitor Function 12:08 Understanding the Immune Niche One Cell at a Time

ATS 2024 • San Diego, CA